Pro Medicus Limited (ASX: PME) has signed a A$53 million contract with BayCare, one of Florida’s leading healthcare systems. The 7-year deal will see BayCare replace its legacy PACS and workflow systems with Visage 7, Pro Medicus’ cloud-based Enterprise Imaging Platform.
Key Highlights
- Contract value: A$53 million over 7 years
- Client: BayCare, a major U.S. healthcare provider with 16 hospitals and 32,000+ employees
- Technology: Visage 7 Viewer and Visage 7 Workflow
- Deployment: Fully cloud-based implementation
- Business model: Transaction-based licensing with potential revenue upside
- Expected Go-Live: Late Q3/Q4 2025
BayCare: A Key Client in the U.S. Healthcare Market
BayCare is a leading healthcare system in Florida, offering a wide range of medical services across hospitals, imaging centers, labs, urgent care clinics, and home care agencies. The Visage 7 rollout will unify BayCare’s imaging workflow, enhancing efficiency and diagnostic capabilities across its network.
Why BayCare Matters for Pro Medicus
✔ Expands PME’s footprint in the North American Integrated Delivery Network (IDN) market
✔ Strengthens PME’s position as a leader in cloud-based healthcare imaging
✔ Adds to PME’s growing list of major U.S. healthcare clients
Leadership Commentary
Dr. Sam Hupert, CEO of Pro Medicus:
“BayCare joins our rapidly growing list of integrated delivery network (IDN) clients. They also join the 70% of all Visage 7 North American clients opting for a cloud-based solution—reinforcing our CloudPACS strategy as the new standard in North American healthcare IT.”
“Our pipeline remains strong, spanning all market segments.”
Market Impact & Outlook
This landmark contract further cements Pro Medicus’ leadership in cloud-based enterprise imaging solutions. With an increasing number of healthcare providers moving to cloud-based imaging, PME continues to benefit from strong market tailwinds in the U.S. healthcare sector.
The transaction-based model also provides revenue upside as imaging volumes grow, making this deal strategically valuable beyond the headline A$53M contract.
With a strong sales pipeline and growing U.S. market penetration, Pro Medicus remains well-positioned for continued expansion and long-term growth.
